The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Abstract
Community-based studies suggest that cannabis products that are high in Δ 9 -tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were randomised to receive oral CBD 600mg ( n=22) or placebo ( n=26), 210 min ahead of intravenous (IV) THC (1.5 mg). Post-THC, there were lower PANSS positive scores in the CBD group, but this did not reach statistical significance. However, clinically significant positive psychotic symptoms (defined a priori as increases ≥3 points) were less likely in the CBD group compared with the placebo group, odds ratio (OR)=0.22 (χ 2 =4.74, p<0.05). In agreement, post-THC paranoia, as rated with the State Social Paranoia Scale (SSPS), was less in the CBD group compared with the placebo group ( t=2.28, p<0.05). Episodic memory, indexed by scores on the Hopkins Verbal Learning Task-revised (HVLT-R), was poorer, relative to baseline, in the placebo pre-treated group (-10.6±18.9%) compared with the CBD group (-0.4%±9.7 %) ( t=2.39, p<0.05). These findings support the idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
The SPQ: A Scale for the Assessment of Schizotypal Personality Based on DSM-III-R Criteria
Raine, A. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.4.555 · Cited by 2,164
Review: Inequalities in healthcare provision for people with severe mental illness
Lawrence, D., & Kisely, S. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382058 · Cited by 649
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Self-citationGreen, C. E. L., Freeman, D., Kuipers, E., Bebbington, P., Fowler, D., Dunn, G., & Garety, P. A. (2008) · Psychological Medicine · doi:10.1017/s0033291707001638 · Cited by 401
Cannabinoids reveal importance of spike timing coordination in hippocampal function
Robbe, D., Montgomery, S. M., Thome, A., Rueda-Orozco, P. E., McNaughton, B. L., & Buzsaki, G. (2006) · Nature Neuroscience · doi:10.1038/nn1801 · Cited by 333
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Morgan, C. J. A., & Curran, H. V. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046649 · Cited by 300
Cited by
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867
Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.002 · Cited by 674
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Self-citationDi Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00117-5 · Cited by 588
Self-citationDi Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt181 · Cited by 470
Self-citationAssociation Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Modelling suicide and unemployment: a longitudinal analysis covering 63 countries, 2000–11
Nordt, C., Warnke, I., Seifritz, E., & Kawohl, W. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00118-7 · Cited by 322
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
Nugent, S. M., Morasco, B. J., O'Neil, M. E., Freeman, M., Low, A., Kondo, K., Elven, C., Zakher, B., Motu'apuaka, M., Paynter, R., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0155 · Cited by 301
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
A systematic review of the antipsychotic properties of cannabidiol in humans
Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253
Cannabis use during adolescent development: Susceptibility to psychiatric illness
Chadwick, B., Miller, M. L., & Hurd, Y. L. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00129 · Cited by 210
Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.367 · Cited by 206
Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00759 · Cited by 190
Lisdahl, K. M., Wright, N. E., Medina-Kirchner, C., Maple, K. E., & Shollenbarger, S. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0019-6 · Cited by 160
Effects of increasing cannabis potency on adolescent health
Wilson, J., Freeman, T. P., & Mackie, C. J. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30342-0 · Cited by 113
da Silva, V. K., de Freitas, B. S., da Silva Dornelles, A., Nery, L. R., Falavigna, L., Ferreira, R. D. P., Bogo, M. R., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8514-7 · Cited by 91
Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine
Pedrazzi, J. F. C., Issy, A. C., Gomes, F. V., Guimarães, F. S., & Del-Bel, E. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3945-7 · Cited by 76
Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62
The Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review
Sorkhou, M., Bedder, R. H., & George, T. P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.630247 · Cited by 61
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Chesney, E., Oliver, D., & McGuire, P. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05905-9 · Cited by 40
Adverse effects of heavy cannabis use: Even plants can harm the brain
Sideli, L., Trotta, G., Spinazzola, E., La Cascia, C., & Di Forti, M. (2021) · Pain · doi:10.1097/j.pain.0000000000001963 · Cited by 36
Can cannabis kill? Characteristics of deaths following cannabis use in England (1998–2020)
Rock, K. L., Englund, A., Morley, S., Rice, K., & Copeland, C. S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221115760 · Cited by 32
Self-citationKamboj, S. K., Walldén, Y. S. E., Falconer, C. J., Alotaibi, M. R., Blagbrough, I. S., Husbands, S. M., & Freeman, T. P. (2018) · Mindfulness · doi:10.1007/s12671-017-0849-0 · Cited by 28
Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood
Hernandez, C. M., Orsini, C. A., Blaes, S. L., Bizon, J. L., Febo, M., Bruijnzeel, A. W., & Setlow, B. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120965931 · Cited by 25
Rømer Thomsen, K., Callesen, M. B., & Feldstein Ewing, S. W. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.025 · Cited by 24
Withey, S. L., Kangas, B. D., Charles, S., Gumbert, A. B., Eisold, J. E., George, S. R., Bergman, J., & Madras, B. K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108629 · Cited by 24
Hutchison, K. E., Hagerty, S. L., Galinkin, J., Bryan, A. D., & Bidwell, L. C. (2019) · Cannabis & Cannabinoid Research · doi:10.1089/can.2018.0052 · Cited by 18
The Changing Legal Landscape of Cannabis Use and Its Role in Youth-onset Psychosis
Wright, A., Cather, C., Gilman, J., & Evins, A. E. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.08.016 · Cited by 16
Mathai, D. S., Holst, M., Rodgman, C., Haile, C. N., Keller, J., Hussain, M. Z., Kosten, T. R., Newton, T. F., & Verrico, C. D. (2018) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.16120328 · Cited by 12
Effects of different methods of cannabis use on cognition and blood THC: A systematic review.
Behzad, D., Patel, S., Besa, R., Chan, A. W. H., Chen, S., Rueda, S., Ruocco, A. C., & Di Ciano, P. (2025) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111399 · Cited by 7
Metadata
- Authors
- Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., Feilding, A., Walker, L., Murray, R. M., & Kapur, S.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-10-05
- Volume
- 27
- Issue
- 1
- Pages
- 19-27
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2006242135
- Cited by
- 462
- References
- 12
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.